Sk Life Science, Inc.

This study tests whether cenobamate, already approved for epilepsy, works well when used alone in adults with partial-onset seizures. About 49 participants will take either 100 mg or 200 mg daily, and researchers will track how many become seizure-free for 26 weeks. The goal is t…

This phase 3 trial is testing the safety and tolerability of the drug cenobamate (Xcopri) in 140 children aged 2 to 17 with partial-onset (focal) seizures. Researchers will monitor side effects, lab results, and drug levels in the blood. The study is open-label, meaning everyone …